Loading ...Moderna Soars After Cancer Vaccine Collab With Merck Meets Primary Endpoint In Phase 2B Trial
“Results are the first demonstration of efficacy for an investigational mRNA cancer treatment in a randomized clinical trial”
A new Moderna cancer vaccine, when paired with Merck’s Keytruda, produced a positive clinical outcome in a mid-stage trial, the company announced this morning.
The drug combination provided a statistically significant result in stopping the recurrence of the skin cancer melanoma after surgery in patients, the Wall Street Journal reported on Tuesday morning.